Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

기사 요약

Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.